Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease

被引:105
作者
Albanese, A
Bonuccelli, U
Brefel, C
Chaudhuri, KR
Colosimo, C
Eichhorn, T
Melamed, E
Pollak, P
Van Laar, T
Zappia, M
机构
[1] Ist Nazl Neurol, I-20133 Milan, Italy
[2] Univ Cattolica Sacro Cuore, Ist Neurol, I-20123 Milan, Italy
[3] Univ Pisa, Neurol Clin, Pisa, Italy
[4] INSERM, U455, Lab Pharmacol Med & Clin, F-31073 Toulouse, France
[5] Kings Coll Hosp London, Dept Neurol, London, England
[6] Univ Roma La Sapienza, Dipartimento Sci Neurol, Rome, Italy
[7] Univ Marburg, Zentrum Nervenheilkunde, Neurol Klin, Marburg, Germany
[8] Sackler Sch Med, Beilinson Med Ctr, Dept Neurol, Tel Aviv, Israel
[9] Univ Grenoble 1, Neurol Serv, Grenoble, France
[10] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands
[11] Univ Catanzaro, Neurol Clin, Catanzaro, Italy
关键词
apomorphine; levodopa; diagnosis; Parkinson disease; treatment;
D O I
10.1002/mds.1069
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Available evidence on the practice of acute pharmacological challenge tests in parkinsonian patients was reviewed by a committee of experts, which achieved a general consensus. The published data deal mainly with the acute administration of levodopa and apomorphine in Parkinson's disease. Such challenge may serve different purposes, e.g., research. diagnosis, or tailoring of treatment. Unique protocols describing the clinical setting and practice parameters are not available. The present paper describes the scientific background and supplies practical guidelines, whenever possible, to perform and evaluate acute challenge tests in parkinsonian syndromes. With the appropriate indication and setting. acute challenge tests are useful in diagnosis and therapy of Parkinson's disease and related disorders. (C) 2001 Movement Disorder Society.
引用
收藏
页码:197 / 201
页数:5
相关论文
共 46 条
[1]  
Albanese A, 1998, NEUROLOGY, V50, pA366
[2]   APOMORPHINE TEST FOR DOPAMINERGIC RESPONSIVENESS - A DOSE ASSESSMENT STUDY [J].
BONUCCELLI, U ;
PICCINI, P ;
DELDOTTO, P ;
ROSSI, G ;
CORSINI, GU ;
MURATORIO, A .
MOVEMENT DISORDERS, 1993, 8 (02) :158-164
[3]  
Chase Thomas N., 1998, Neurology, V50, pS17
[4]   CLINICAL USEFULNESS OF APOMORPHINE IN MOVEMENT-DISORDERS [J].
COLOSIMO, C ;
MERELLO, M ;
ALBANESE, A .
CLINICAL NEUROPHARMACOLOGY, 1994, 17 (03) :243-259
[5]   SOME SPECIFIC CLINICAL-FEATURES DIFFERENTIATE MULTIPLE SYSTEM ATROPHY (STRIATONIGRAL VARIETY) FROM PARKINSONS-DISEASE [J].
COLOSIMO, C ;
ALBANES, A ;
HUGHES, AJ ;
DEBRUIN, VMS ;
LEES, AJ .
ARCHIVES OF NEUROLOGY, 1995, 52 (03) :294-298
[6]  
Critchley P H, 1988, J Neural Transm Suppl, V27, P55
[7]  
Defer GL, 1999, MOVEMENT DISORD, V14, P572, DOI 10.1002/1531-8257(199907)14:4<572::AID-MDS1005>3.0.CO
[8]  
2-C
[9]   LEVODOPA-INDUCED DIPHASIC DYSKINESIAS IMPROVED BY SUBCUTANEOUS APOMORPHINE [J].
DESAINTVICTOR, JF ;
POLLAK, P ;
GERVASON, CL ;
PERRET, J .
MOVEMENT DISORDERS, 1992, 7 (03) :283-284
[10]   Levodopa ethylester: A novel rescue therapy for response fluctuations in Parkinson's disease [J].
Djaldetti, R ;
Melamed, E .
ANNALS OF NEUROLOGY, 1996, 39 (03) :400-404